Boxes of Ozempic and Mounjaro, semaglutide and tirzepatide injection drugs used for treating type 2 diabetes and made by Novo Nordisk and Lilly. Photo taken at HealthyWayRx Pharmacy Canada – December 2023.
A recent article published on Reuters states that according to an analysis of health records and data, overweight or obese adults using Eli Lilly’s drug Mounjaro lost more weight and lost it faster compared to those taking Novo Nordisk’s rival drug.
The study found that within a year, 42.3% of patients on tirzepatide (Mounjaro) had lost at least 15% of their weight, while only 19.3% of patients on semaglutide (Ozempic) achieved the same.
After considering individual risk factors, patients taking Mounjaro were more likely to lose 5%, 10%, and 15% of their body weight compared to those taking Ozempic. The study analyzed data from 9,193 patients receiving Mounjaro and a matched number of patients receiving Ozempic.
The weight loss difference between the two drugs increased over time, with the Mounjaro group losing an average of 7.2% more weight than the Ozempic group after 12 months. Rates of gastrointestinal adverse events were similar between the two groups.
It’s worth noting that half of the study participants were using the drugs for weight loss only, despite them being intended for use by people with type 2 diabetes. The study has not been peer-reviewed, and further research is underway to compare the weight loss formulations of the two drugs in patients without type 2 diabetes.
Please consult your physician for personalized medical advice. Always seek the advice of a physician or other qualified healthcare provider with any questions regarding a medical condition. Never disregard or delay seeking professional medical advice or treatment because of something you have read.